Showing 1 - 10 of 9,652
Persistent link: https://www.econbiz.de/10011748246
Persistent link: https://www.econbiz.de/10011846513
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
In Paragraph (iv) pharmaceutical cases, a patent-litigation decision often determines whether a brand-firm monopoly continues or generic entry occurs. Using unique patent litigation data and an event-study approach that accounts for probabilistic district court decisions and an appellate...
Persistent link: https://www.econbiz.de/10014143049
Persistent link: https://www.econbiz.de/10012264635
Persistent link: https://www.econbiz.de/10011297589
Persistent link: https://www.econbiz.de/10012433661
We analyze, theoretically and empirically, how salience affects the market reaction to innovation announcements …, there will be a stock return drift following innovation announcements, with the former magnitude increasing and the latter …
Persistent link: https://www.econbiz.de/10014352443
We analyze, theoretically and empirically, the implications of salience on innovation announcements in the … biopharmaceutical industry. We hypothesize that equity market investors are more likely to pay attention to an innovation announcement … that is more salient: thus, investors pay more attention to FDA drug approvals of pharmaceuticals compared to that paid to …
Persistent link: https://www.econbiz.de/10014352748
Persistent link: https://www.econbiz.de/10001491302